Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects

James G. Kublin, Sebastian A. Mikolajczak, Brandon Wilder, Matt E. Fishbaugher, Annette Seilie, Lisa Shelton, Tracie VonGoedert, Melike Firat, Sara Magee, Emma Fritzen, Will Betz, Heather S. Kain, Dorender A. Dankwa, Ryan W.J. Steel, Ashley M. Vaughan, D. Noah Sather, Sean C. Murphy, Stefan H.I. Kappe

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Immunization of humans with whole sporozoites confers complete, sterilizing immunity against malaria infection. However, achieving consistent safety while maintaining immunogenicity of whole parasite vaccines remains a formidable challenge. We generated a genetically attenuated Plasmodium falciparum (Pf) malaria parasite by deleting three genes expressed in the pre-erythrocytic stage (Pf p52-/p36-/sap1-). We then tested the safety and immunogenicity of the genetically engineered (Pf GAP3KO) sporozoites in human volunteers. Pf GAP3KO sporozoites were delivered to 10 volunteers using infected mosquito bites with a single exposure consisting of 150 to 200 bites per subject. All subjects remained blood stage-negative and developed inhibitory antibodies to sporozoites. GAP3KO rodent malaria parasites engendered complete, protracted immunity against infectious sporozoite challenge in mice. The results warrant further clinical testing of Pf GAP3KO and its potential development into a vaccine strain.

Original languageEnglish (US)
Article numbereaad9099
JournalScience Translational Medicine
Volume9
Issue number371
DOIs
StatePublished - Jan 4 2017
Externally publishedYes

Fingerprint

Sporozoites
Plasmodium falciparum
Parasites
Bites and Stings
Malaria
Volunteers
Immunity
Vaccines
Safety
Falciparum Malaria
Culicidae
Rodentia
Immunization
Antibodies
Infection
Genes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Kublin, J. G., Mikolajczak, S. A., Wilder, B., Fishbaugher, M. E., Seilie, A., Shelton, L., ... Kappe, S. H. I. (2017). Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects. Science Translational Medicine, 9(371), [eaad9099]. https://doi.org/10.1126/scitranslmed.aad9099

Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects. / Kublin, James G.; Mikolajczak, Sebastian A.; Wilder, Brandon; Fishbaugher, Matt E.; Seilie, Annette; Shelton, Lisa; VonGoedert, Tracie; Firat, Melike; Magee, Sara; Fritzen, Emma; Betz, Will; Kain, Heather S.; Dankwa, Dorender A.; Steel, Ryan W.J.; Vaughan, Ashley M.; Sather, D. Noah; Murphy, Sean C.; Kappe, Stefan H.I.

In: Science Translational Medicine, Vol. 9, No. 371, eaad9099, 04.01.2017.

Research output: Contribution to journalArticle

Kublin, JG, Mikolajczak, SA, Wilder, B, Fishbaugher, ME, Seilie, A, Shelton, L, VonGoedert, T, Firat, M, Magee, S, Fritzen, E, Betz, W, Kain, HS, Dankwa, DA, Steel, RWJ, Vaughan, AM, Sather, DN, Murphy, SC & Kappe, SHI 2017, 'Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects', Science Translational Medicine, vol. 9, no. 371, eaad9099. https://doi.org/10.1126/scitranslmed.aad9099
Kublin, James G. ; Mikolajczak, Sebastian A. ; Wilder, Brandon ; Fishbaugher, Matt E. ; Seilie, Annette ; Shelton, Lisa ; VonGoedert, Tracie ; Firat, Melike ; Magee, Sara ; Fritzen, Emma ; Betz, Will ; Kain, Heather S. ; Dankwa, Dorender A. ; Steel, Ryan W.J. ; Vaughan, Ashley M. ; Sather, D. Noah ; Murphy, Sean C. ; Kappe, Stefan H.I. / Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects. In: Science Translational Medicine. 2017 ; Vol. 9, No. 371.
@article{d535e7b3fbe94ff59cfa98606cfa62b3,
title = "Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects",
abstract = "Immunization of humans with whole sporozoites confers complete, sterilizing immunity against malaria infection. However, achieving consistent safety while maintaining immunogenicity of whole parasite vaccines remains a formidable challenge. We generated a genetically attenuated Plasmodium falciparum (Pf) malaria parasite by deleting three genes expressed in the pre-erythrocytic stage (Pf p52-/p36-/sap1-). We then tested the safety and immunogenicity of the genetically engineered (Pf GAP3KO) sporozoites in human volunteers. Pf GAP3KO sporozoites were delivered to 10 volunteers using infected mosquito bites with a single exposure consisting of 150 to 200 bites per subject. All subjects remained blood stage-negative and developed inhibitory antibodies to sporozoites. GAP3KO rodent malaria parasites engendered complete, protracted immunity against infectious sporozoite challenge in mice. The results warrant further clinical testing of Pf GAP3KO and its potential development into a vaccine strain.",
author = "Kublin, {James G.} and Mikolajczak, {Sebastian A.} and Brandon Wilder and Fishbaugher, {Matt E.} and Annette Seilie and Lisa Shelton and Tracie VonGoedert and Melike Firat and Sara Magee and Emma Fritzen and Will Betz and Kain, {Heather S.} and Dankwa, {Dorender A.} and Steel, {Ryan W.J.} and Vaughan, {Ashley M.} and Sather, {D. Noah} and Murphy, {Sean C.} and Kappe, {Stefan H.I.}",
year = "2017",
month = "1",
day = "4",
doi = "10.1126/scitranslmed.aad9099",
language = "English (US)",
volume = "9",
journal = "Science Translational Medicine",
issn = "1946-6234",
publisher = "American Association for the Advancement of Science",
number = "371",

}

TY - JOUR

T1 - Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects

AU - Kublin, James G.

AU - Mikolajczak, Sebastian A.

AU - Wilder, Brandon

AU - Fishbaugher, Matt E.

AU - Seilie, Annette

AU - Shelton, Lisa

AU - VonGoedert, Tracie

AU - Firat, Melike

AU - Magee, Sara

AU - Fritzen, Emma

AU - Betz, Will

AU - Kain, Heather S.

AU - Dankwa, Dorender A.

AU - Steel, Ryan W.J.

AU - Vaughan, Ashley M.

AU - Sather, D. Noah

AU - Murphy, Sean C.

AU - Kappe, Stefan H.I.

PY - 2017/1/4

Y1 - 2017/1/4

N2 - Immunization of humans with whole sporozoites confers complete, sterilizing immunity against malaria infection. However, achieving consistent safety while maintaining immunogenicity of whole parasite vaccines remains a formidable challenge. We generated a genetically attenuated Plasmodium falciparum (Pf) malaria parasite by deleting three genes expressed in the pre-erythrocytic stage (Pf p52-/p36-/sap1-). We then tested the safety and immunogenicity of the genetically engineered (Pf GAP3KO) sporozoites in human volunteers. Pf GAP3KO sporozoites were delivered to 10 volunteers using infected mosquito bites with a single exposure consisting of 150 to 200 bites per subject. All subjects remained blood stage-negative and developed inhibitory antibodies to sporozoites. GAP3KO rodent malaria parasites engendered complete, protracted immunity against infectious sporozoite challenge in mice. The results warrant further clinical testing of Pf GAP3KO and its potential development into a vaccine strain.

AB - Immunization of humans with whole sporozoites confers complete, sterilizing immunity against malaria infection. However, achieving consistent safety while maintaining immunogenicity of whole parasite vaccines remains a formidable challenge. We generated a genetically attenuated Plasmodium falciparum (Pf) malaria parasite by deleting three genes expressed in the pre-erythrocytic stage (Pf p52-/p36-/sap1-). We then tested the safety and immunogenicity of the genetically engineered (Pf GAP3KO) sporozoites in human volunteers. Pf GAP3KO sporozoites were delivered to 10 volunteers using infected mosquito bites with a single exposure consisting of 150 to 200 bites per subject. All subjects remained blood stage-negative and developed inhibitory antibodies to sporozoites. GAP3KO rodent malaria parasites engendered complete, protracted immunity against infectious sporozoite challenge in mice. The results warrant further clinical testing of Pf GAP3KO and its potential development into a vaccine strain.

UR - http://www.scopus.com/inward/record.url?scp=85010685235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85010685235&partnerID=8YFLogxK

U2 - 10.1126/scitranslmed.aad9099

DO - 10.1126/scitranslmed.aad9099

M3 - Article

VL - 9

JO - Science Translational Medicine

JF - Science Translational Medicine

SN - 1946-6234

IS - 371

M1 - eaad9099

ER -